Pliant Therapeutics to Present New Solid Tumor Trial Data
The company will share early-stage research at the 41st Society for Immunotherapy of Cancer meeting in Phoenix this November.
Updated on Oct. 29, 2026 in Biotech
Live Poll
Do clinical research trial updates indicate real progress in treating advanced solid tumors?
Pliant Therapeutics is scheduled to present data from its ongoing Phase 1a/1b FORTIFY clinical trial at the Society for Immunotherapy of Cancer annual meeting in Phoenix from November 4 to 8, 2026. The research, which remains in the clinical trial stage, focuses on the company’s dual-selective integrin inhibitor candidate, PLN-101095.
Why it matters
The company is evaluating how targeting specific integrins can potentially enhance antitumor activity when combined with established immunotherapies. This research addresses the persistent challenge of overcoming treatment resistance in patients with solid tumors.
The FORTIFY trial (NCT06270706) employs an open-label design to test PLN-101095, a dual-selective inhibitor targeting αvβ8 and αvβ1 integrins—proteins involved in cell signaling and tumor progression. Researchers are evaluating these targets to determine if they effectively modulate the tumor microenvironment for better immunotherapy outcomes.
The players
Pliant Therapeutics
A clinical-stage biotechnology company developing small-molecule therapies for fibrotic diseases and cancer.
Nika Rajabian
Researcher presenting findings on integrin targeting and immune checkpoint inhibition.
Martin L. Decaris
Researcher presenting data on plasma biomarkers related to the company's lead therapeutic candidate.
The details
The FORTIFY trial uses a dose-escalation design to assess the safety and pharmacokinetics of PLN-101095 in patients with solid tumors. Participants undergo a 14-day monotherapy lead-in period before pembrolizumab—a monoclonal antibody that enables the immune system to recognize and attack cancer cells—is introduced. The trial explores whether inhibiting specific integrins can prevent tumor immune evasion.
Timeline
November 4 - 8, 2026: 41st Annual Meeting of the Society for Immunotherapy of Cancer in Phoenix.
November 6, 2026: Poster presentation by Nika Rajabian regarding integrin targeting.
November 7, 2026: Poster presentation by Martin L. Decaris regarding PLN-101095 plasma biomarkers.
The Tech Race
Pliant Therapeutics is currently benchmarking its dual-selective integrin inhibitor against existing standard-of-care immunotherapies. This research marks an attempt to expand the efficacy of checkpoint inhibitors like pembrolizumab through the specific modulation of the tumor microenvironment.
The findings presented in Phoenix are intended for the scientific and clinical oncology communities currently monitoring the safety of integrin-inhibitor combinations. Patients interested in the trial's progression should consult their oncologists regarding clinical trial eligibility under NCT06270706.
The takeaway
These presentations provide early insight into whether dual-selective integrin inhibition can improve outcomes for solid tumor patients when paired with standard therapy. Future observers should track upcoming updates from the FORTIFY trial to determine if the 1,000 mg dosing strategy yields sustained clinical benefit.
Further reading
For more on the current state of clinical research, visit the Biotech section.
Live Poll
Do clinical research trial updates indicate real progress in treating advanced solid tumors?
